AI assistant
OptimizeRx Corp — Regulatory Filings 2016
Nov 9, 2016
33090_rns_2016-11-09_64ee23e8-ac5b-47d1-aa3e-399920916479.zip
Regulatory Filings
Open in viewerOpens in your device viewer
8-K 1 f8k110716_optimizerxcorp.htm CURRENT REPORT
Field: Rule-Page
Field: /Rule-Page
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Field: Rule-Page
Field: /Rule-Page
FORM 8-K
Field: Rule-Page
Field: /Rule-Page
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2016
| OptimizeRx
| Corporation |
|---|
| (Exact |
| name of registrant as specified in its charter) |
| Nevada | 000-53605 | 26-1265381 |
|---|---|---|
| (State | ||
| or other jurisdiction of incorporation) | (Commission | |
| File Number) | (I.R.S. | |
| Employer Identification No.) |
| 400
| Water Street, Suite 200, Rochester, MI | 48307 |
|---|---|
| (Address | |
| of principal executive offices) | (Zip |
| Code) |
Registrant’s telephone number, including area code: 248.651.6568
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | --- | --- | | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
SECTION 2 – Financial Information
Item 2.02 Results of Operations and Financial Condition.
On November 7, 2016, we issued a press release announcing the results of operations for the quarter ended September 30, 2016.
The press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. The information furnished under this Item 2.02 and Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, regardless of any general incorporation by reference language in such filing, except as shall be expressly set forth by specific reference in any such filing.
Section 8 – Other Events
Item 8.01 Other Events
On November 7, 2016, the Company held a conference call to discuss the Company’s earnings for the quarter ended September 30, 2016 and other matters of business, a transcript of which is furnished herewith as Exhibit 99.2 and is incorporated herein by reference.
The transcript is furnished with this Current Report on Form 8-K as Exhibit 99.2. The information furnished under this Item 8.01 and Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, regardless of any general incorporation by reference language in such filing, except as shall be expressly set forth by specific reference in any such filing.
SECTION 9 – Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release, dated November 7, 2016 |
| 99.2 | Transcript, dated November 7, 2016 |
Field: Page; Sequence: 2; Options: NewSection; Value: 2
Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OptimizeRx
| Corporation |
|---|
| /s/ |
| Douglas Baker |
| Douglas Baker |
| Chief Financial |
| Officer |
| Date: November |
| 9, 2016 |
3
Field: Rule-Page
Field: /Rule-Page